Celastrol attenuates diabetic kidney disease progression by repressing senescence of renal tubular epithelial cells
Celastrol may be a promising candidate drug for the treatment of DKD. It can treat DKD by reversing the imbalance of the immune-inflammatory system mediated by the AKT/NF-κB/TNF-α signaling during the progression of the disease and may also delay the progression of DKD through its anti-aging effect.
Authors
- Jingyong Sun (ORCID: https://orcid.org/0000-0002-7698-4523)
- Xiaodong Mu (ORCID: https://orcid.org/0000-0002-0362-0083)
- Yixuan Tang (ORCID: https://orcid.org/0000-0003-2755-8269)
- Zewei Sun
- Siqi Lei (ORCID: https://orcid.org/0009-0002-6196-0913)
- Yajun Zhang (ORCID: https://orcid.org/0000-0002-0689-475X)
- Meng Wang (ORCID: https://orcid.org/0000-0002-1578-3154)
Institutions
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Aging
- Published
- 2025-11-27
- DOI
- https://doi.org/10.3389/fragi.2025.1657947
- Primary Topic
- Natural Compounds in Disease Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shandong Province
- Shandong First Medical University